Gene therapies that are based on adeno-associated virus (AAV) vectors have demonstrated immense potential to treat and even cure previously intractable diseases, but unfortunately the costs are ...

Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments ...

The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...

Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple AAV ...

Trisk Bio Ltd, a UK-based AAV contract development and manufacturing organisation (CDMO), and NanoMosaic, Inc., a leader in advanced analytical technologies for cell and gene therapy, today announced ...

Pharmaron Biologics, Liverpool, UK, is a commercial development and manufacturing organization (CDMO) that offers a range of unique end-to-end laboratory services for the development and manufacture ...

Epicrispr Biotechnologies ("Epicrispr"), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics ( ...

VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -- Data from eight ASGCT presentations ...

There is no need to waste important AAV samples. Bio-Techne’s automated, high-throughput systems allow the characterization of AAVs in sample volumes as low as 3 µL while maintaining high levels of ...

OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the ...